Roche Enters $2.3 Billion Blood-Cancer Drug Deal With Nurix Therapeutics
RSS SUMMARY · AGGREGATED FROM TWSJ
The Swiss drugmaker said it would pay Nurix $700 million upfront, while development costs would be split 60-40, with Roche taking the larger share.
The Swiss drugmaker said it would pay Nurix $700 million upfront, while development costs would be split 60-40, with Roche taking the larger share.
The Swiss drugmaker said it would pay Nurix $700 million upfront, while development costs would be split 60-40, with Roche taking the larger share.
Continue Reading
The full story continues on The Wall Street Journal.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.
The Source
TWSJ
World News
Chinese AI Startup StepFun Set to File for Hong Kong IPO
TWSJ·57m ago·3 min read
World News
ECB Expected to Be First Among Peers to Raise Key Rate in Response to Conflict
TWSJ·20m ago·3 min read
Business
German Factory Orders Fell Back in April
TWSJ·42m ago·3 min read
Health
Novo Nordisk Weight-Loss Pill Prescriptions Hit Three Million Since Launch
TWSJ·29m ago·3 min read
Related
On this beat
Business
All the Ways Europe Is Ditching American Technology
WIRED·1h ago·3 min read
Business
German Factory Orders Fell Back in April
TWSJ·42m ago·3 min read
Business
Ukraine lined its roads with enough anti-drone netting this year to cover the length of Florida
BI·49m ago·3 min read
Business
Haleon to Invest $233.5 Million in India Plant Amid Push Into Emerging Markets
TWSJ·1h ago·3 min read